Olomoucine is a purine derivative that inhibits CDKs and exhibits anti-inflammatory, neuroprotective, and anticancer activities. In macrophages, olomoucine decreases levels of NO and iNOS and suppresses activation of NF-κB. In leukemia cells, olomoucine alters cell cycle progression and inhibits proliferation. Additionally, this compound prevents cathepsin L translocation and the induction of autophagy in neurons, protecting against 6-OHDA-induced toxicity.
| Cas No. | 101622-51-9 |
|---|---|
| Purity | ≥98% |
| Formula | C15H18N6O |
| Formula Wt. | 298.34 |
| Chemical Name | 6-Benylamino-2-(2-hydroxyethylamino)-9-methyl- purine |
| IUPAC Name | 2-[[6-(benzylamino)-9-methylpurin-2-yl]amino]ethanol |
| Synonym | 2-(Hydroxyethylamino)-6-benzylamino-9-methylpurine |
| Melting Point | 120-130°C |
| Solubility | Soluble in DMSO or methanol. |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | O4556 MSDS PDF |
|---|---|
| Info Sheet | O4556 Info Sheet PDF |
Wandl S, Wesierska-Gadek J. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells? Ann N Y Acad Sci. 2009 Aug;1171:242-9. PMID: 19723061.
Fei XF, Qin ZH, Xiang B, et al. Olomoucine inhibits cathepsin L nuclear translocation, activates autophagy and attenuates toxicity of 6-hydroxydopamine. Brain Res. 2009 Apr 6;1264:85-97. PMID: 19368812.
